Trial · NCT00232180
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date | Eplerenone: Double-blind Phase | 249 | participants | ||
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date | Placebo: Double-blind Phase | 356 | participants | ||
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated) | Eplerenone: Double-blind Phase | 288 | participants | ||
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated) | Placebo: Double-blind Phase | 392 | participants | ||
| Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated) | Eplerenone: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 270 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated) | Placebo: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 376 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated) | Eplerenone: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 311 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated) | Placebo: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 418 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated) | Eplerenone: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 171 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated) | Placebo: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 213 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated) | Eplerenone: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 205 | participants | |
| Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated) | Placebo: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 253 | participants | |
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated) | Eplerenone: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 147 | participants | |
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated) | Placebo: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 185 | participants | |
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated) | Eplerenone: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 178 | participants | |
| Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated) | Placebo: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 215 | participants | |
| Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated) | Eplerenone: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 408 | participants | |
| Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated) | Placebo: Double-blind Phase | Up to 50 months (cut-off) (n= 1364, 1373) | 491 | participants | |
| Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated) | Eplerenone: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 463 | participants | |
| Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated) | Placebo: Double-blind Phase | Up to 59.5 months (complete DB) (n= 1367, 1376) | 552 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00232180/results